Region Stockholm engages SYNLAB to expand its medical diagnostic services in Sweden. * The Health and Medical Care Committee awarded SYNLAB Sverige AB the contract for the provision of services within clinical laboratory medicine in the Stockholm region. * This agreement enables SYNLAB to strengthen the region's diagnostic infrastructure and significantly expand its role and presence within the healthcare landscape in Sweden. * SYNLAB will work closely with the regional authority to expand its network while continuing to provide reliable, accessible and high-quality service that benefits patients and professionals. SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, announced today that SYNLAB Sverige AB has been selected by Region Stockholm to provide medical diagnostic services throughout the county. The decision reflects the region's confidence in SYNLAB as a capable and trusted partner for the future of healthcare. The new agreement brings a modern and high-quality medical diagnostic solution to Region Stockholm. It allows SYNLAB to expand its presence in the region and strengthen an essential part of the healthcare system's diagnostic infrastructure. The assignment covers clinical chemistry including pharmacology, clinical microbiology, clinical immunology, and clinical pathology and cytology, as well as the processes needed to ensure safe and efficient sample handling. Within the framework of the agreement, SYNLAB will also operate a network of blood collection points (BCPs) in the western parts of the Stockholm County, the inner city and the southwestern areas. The agreement spans a period of five years, with the option to extend, and operations are planned to begin in April 2027. "We are proud of the trust placed in us to deliver laboratory and sample-collection services to Region Stockholm. Medical diagnostics are vital to the healthcare system. We look forward to working with the region to expand SYNLAB's modern and reliable diagnostic service and to provide strong value for patients and healthcare professionals," says Johanna Kristoffersson, Chief Executive Officer of SYNLAB Sverige AB. With its strong track record of building and managing large-scale operations tailored to local needs and environment, SYNLAB looks forward to expanding its services on behalf of Region Stockholm and contributing to care excellence across the wider region.

Cinven has completed the sale of an indirect minority stake in SYNLAB to Labcorp, a global leader in laboratory services. SYNLAB, a major player in medical diagnostics in Europe, achieved revenues of €2.62 billion in 2024. The companies plan to explore opportunities for Labcorp's specialty tests in Europe and potential collaborations. Labcorp, with nearly 70,000 employees, supported over 75% of new FDA-approved drugs in 2024.